HCL Technologies Launches a Global Hackathon to Identify Long-Term Technology Solutions to the COVID-19 Pandemic
20.8.2020 15:00:00 EEST | Business Wire | Press release
HCL Technologies , (HCL), a leading global technology company, today announced a multi-phase hackathon, “Better Health Hackathon: #CodeforCOVID19,” to crowdsource technology innovation to find solutions for the immediate and long-term societal impact of the COVID-19 pandemic, including pandemic containment and prevention; diagnosis, treatment and therapeutic management; recovery and return to normal; and systemic solutions for future crises.
As part of the program, HCL has partnered with Microsoft and International SOS, the world's largest medical and travel security services firm, who are providing business and technical oversight to the contest and feedback to team entries. In addition, the Better Health Hackathon is bringing together a wide-ranging and prestigious group of executives and companies, across multiple industries, to serve as judges and advisory panel members. This includes scholars from Johns Hopkins University, University of Cambridge, Tuck School of Business, The University of Queensland, Indian Institute of Technology, Kanpur, and subject matter experts from HCL.
The competition is open to technology innovators, entrepreneurs and problem solvers from the global developer community. To date the Better Health Hackathon has received more than 7500 registrations from 600+ unique organizations and academic institutions spanning 350 locations across 52 countries. To engage top talent in the coding community, the Hackathon is partnering with BeMyApp to leverage their expansive network of coders and tech enthusiasts. The Hackathon is open to eligible participants who are at least 18 years of age.
“The unique capabilities and strength of HCL’s global ecosystem of partners, coupled with the immense talent and best minds from the tech, developer and entrepreneur communities, enables us to make a significant contribution during the COVID-19 pandemic,” said Arthur Filip, Executive Vice President, Sales Transformation & Marketing, HCL Technologies. “Technology has a big role to play in alleviating the challenges brought on by the pandemic, addressing solutions for successful containment and the reorientation of business and society. We are honored to curate a very enthusiastic, committed and deeply talented global community to help us in this important work.”
Neeraj Balani, Managing Director, International SOS, India, said, “We are honored to be part of this initiative with our customer, HCL Technologies, and are confident that the outcomes will provide breakthroughs and benefits for employee health and wellness, which ultimately has a large impact on empowering business resilience, continuity and sustainability.”
Takuya Hirano, VP, Partner Services, Microsoft Corp., said, “This hackathon presents an opportunity for technology experts and innovative thinkers to showcase how advanced technology can help identify solutions to challenging problems facing societies. Technology can serve as a vehicle to drive new solutions that help improve the wellbeing of our communities and prepare us for future health challenges.”
Specifically, the HCL Better Health Hackathon: #CodeforCOVID19 will address the following areas:
-
Prevention and containment: #StayAtHome
- This track explores solutions that better safeguard the most vulnerable in our communities, better communicate credible information, and help people better cope with the challenges of self-isolation. This track will examine: How can technology aid efforts to #FlattenTheCurve by offering a better quality of life to encourage people to #StayAtHome.
-
Diagnosis, treatment & therapeutic management
- This track focuses on ways to help better protect and equip frontline healthcare workers and first responders, and to better serve those individuals and organizations seeking treatments and cures for COVID-19 with technology solutions.
-
Recovery and return to normal
- This track dives into the next phase of society after shutdown orders are removed. In the absence of a tested and available vaccine or therapeutic treatments against COVID-19, how can technology safeguard communities against a relapse of an outbreak, once social distancing and other restrictions are lifted throughout the world, allowing people to return to public spaces.
-
Systemic solutions for crises and pandemic management
- This track ideates innovative uses for next-gen technologies to plan for the long-term implications of COVID-19 and better prepare for future global pandemic-related challenges across healthcare and public services ecosystems.
About HCL Technologies
HCL Technologies (HCL) empowers global enterprises with technology for the next decade today. HCL’s Mode 1-2-3 strategy through its deep-domain industry expertise, customer-centricity and entrepreneurial culture of ideapreneurship™ enables businesses transform into next-gen enterprises.
HCL offers its services and products through three business units - IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in areas of Applications, Infrastructure, Digital Process Operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering while under P&P, HCL provides modernized software products to global clients for their technology and industry specific requirements. Through its cutting-edge co-innovation labs, global delivery capabilities and broad global network, HCL delivers holistic services in various industry verticals, categorized under Financial Services, Manufacturing, Technology & Services, Telecom & Media, Retail & CPG, Life Sciences & Healthcare and Public Services.
As a leading global technology company, HCL takes pride in its diversity, social responsibility, sustainability and education initiatives. As of 12 months ended June 30, 2020, HCL has a consolidated revenue of US $ 9.93 billion and its 150,287 ideapreneurs operate out of 49 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200820005438/en/
Contact information
For further details, please contact:
HCL Technologies
Anne Coyle, US
Anne.coyle@hcl.com
Elka Ghudial, Europe
Elka.ghudial@hcl.com
Devneeta Pahuja, India and APAC
Devneeta.p@hcl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity30.1.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learned about the effects of menopause on the skin by going through it themselves, with most finding out about it in their 40s.2 However, over 30% would have liked to learn about this in their 30s and over 50% are at best neutral or dissatisfied with their knowledge on the topic.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129610958/en/ To address this knowledge gap, Galderma will leverage its expertise in dermatology to advance awareness, understanding, education, and treatment approaches for menopause-related skin changes. With around 85% of aesthetic patients being female, it is important to
Convera Appoints Industry Leader Meaghan Riley as Chief Commercial Officer to Scale Commercial Growth and Expand Revenue Opportunities29.1.2026 18:14:00 EET | Press release
Convera, a global leader in commercial payments, today announces the appointment of Meaghan Riley to Chief Commercial Officer, as the company continues its growth trajectory, expands to new markets, and drives scalable revenue opportunities across geographies and sectors. Prior to Convera, Meaghan was Chief Operating Officer for Google Cloud North America, where she led a major go-to-market transformation and launched high-growth segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129799440/en/ Meaghan Riley, Chief Commercial Officer, Convera “Meaghan’s impressive career journey and proven track record brings exceptional experience and unique assets that will strengthen our leadership team at this pivotal moment in Convera’s journey,” said Patrick Gauthier, CEO, Convera. “Meaghan’s leadership will be instrumental in delivering on our commitment to make global business payments simpler and smarter—serving our customer
New Year, New Solutions: AMRA Medical Continues Commitment to Innovation & Data-Driven Excellence29.1.2026 17:23:00 EET | Press release
AMRA Medical, the global leader in MRI-based fat distribution and muscle composition analytics, is excited to share our brand repositioning supported by the launch of a refreshed website and the introduction of a new tagline, “Insights Within.” This strategic update reflects AMRA’s commitment to placing clients and collaborators at the center of our vision: to be the most trusted, insights-driven imaging partner in the pursuit of preventing and curing disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260129457626/en/ The new website provides a more structured and transparent presentation of AMRA’s biomarkers and research services, enabling our partners to have a clear understanding of our offerings, as well as the scientific value and applications of these solutions. For the first time, we’re introducing Imaging Biomarkers and Insights Biomarkers: clearly-defined, intentional offerings that are designed with your trial
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
